According to an AP story, the FDA has required a Black box warning, the most serious warning available for anemia drugs marketed by Amgen Inc. and Johnson & Johnson. The new warnings include advisories regarding the risk of death and tumor growth in patients with certain types of cancer, including breast cancer and cervical cancer. Amgen’s Aranesp and Epogen are implicated in these cancer risks, as well as Procrit, made by Johnson & Johnson. According to the news story and FDA release, the drugs treat the blood-disorder anemia in patients with kidney failure or who are undergoing chemotherapy.
Interestingly, the addition of the Black Box Drug warning is just before a meeting next week where the FDA advisory committee will review the risks of these anemia drugs.
It is speculated that the FDA could order a recall of all such anemia drugs or a separate Aranesp recall, Epogen recall, or Procrit recall.
The justice attorneys of Aylstock, Witkin, Kreis & Overholtz are investingating cases of anemia drugs causing tumor growth, cancer growth and cancer death in anemia patients or those undergoing cancer treatment. If you or a loved one would wlike more information about Aranesp lawsuits , Epogen lawsuits, or Procrit lawsuits, please visit the anemia drug black box website or to find an anemia drug lawyer, visit www.awkolaw.com.